| Literature DB >> 27518040 |
Maria W Gunnes1,2, Rolv Terje Lie1,3, Tone Bjørge1,4, Astri Syse5, Ellen Ruud6,7, Finn Wesenberg4,6,7, Dag Moster1,2,3.
Abstract
BACKGROUND: The impact of cancer on socioeconomic outcomes is attracting attention as the number of survivors of cancer in young age continues to rise. This study examines economic independence in a national cohort of survivors of cancer at a young age in Norway.Entities:
Keywords: adolescent; cancer; childhood; cohort studies; employment; income; occupations; socioeconomic factors; survivors; young adult
Mesh:
Year: 2016 PMID: 27518040 PMCID: PMC5157778 DOI: 10.1002/cncr.30253
Source DB: PubMed Journal: Cancer ISSN: 0008-543X Impact factor: 6.860
Characteristics of Cancer Survivors by Cancer Site Stratified by Sex, Age, and Period of Cancer Diagnosis
| No. (%) | |||||
|---|---|---|---|---|---|
| Age at Cancer Diagnosis | |||||
| 0‐14 Years | 15‐24 Years | ||||
| Cancer Site | Men | Women | Men | Women | Total |
| Leukemia | 343 (28.8) | 290 (30.7) | 128 (6.8) | 84 (5.9) | 845 (15.5) |
| Lymphoma | 122 (10.2) | 57 (6) | 313 (16.8) | 229 (16) | 721 (13.3) |
| CNS tumors | 321 (26.9) | 222 (23.5) | 272 (14.6) | 259 (18.1) | 1074 (19.7) |
| Testicular cancer | 43 (3.6) | 695 (37.2) | 738 (13.6) | ||
| Malignant melanoma | 14 (1.2) | 25 (2.6) | 117 (6.2) | 323 (22.5) | 479 (8.8) |
| Bone and soft tissue tumors | 110 (9.2) | 111 (11.7) | 169 (9.1) | 105 (7.3) | 495 (9.1) |
| Female genital tract tumors | 25 (2.6) | 143 (10) | 168 (3.1) | ||
| Other | 240 (20.1) | 216 (22.8) | 174 (9.3) | 290 (20.2) | 920 (16.9) |
| All cancer | 1193 (100) | 946 (100) | 1868 (100) | 1433 (100) | 5440 (100) |
Abbreviation: CNS, central nervous system.
Cancer sites are based on International Classification of Diseases (7th edition) site codes and on Manual of Tumor Nomenclature and Coding and International Classification of Diseases for Oncology (2nd edition) morphology codes.
Hazard Ratios and 95% Confidence Intervals for Receipt of Governmental Financial Assistance in Cancer Survivors, by Cancer Site and Age at Diagnosis, Compared With Cancer‐Free Individuals
| Men | Women | ||||||
|---|---|---|---|---|---|---|---|
| HR (95% CI) | HR (95% CI) | ||||||
| Cancer Site | No. of FA Recipients | Model 1 | Model 2 | Mean Age at FA, y | Model 1 | Model 2 | Mean age at FA, y |
| Noncancer | 239,996 | Reference | Reference | 23.1 | Reference | Reference | 23.1 |
| Leukemia | 134 | 1.24 (0.95‐1.60) | 1.15 (0.86‐1.53) | 22.6 | 1.72 (1.34‐2.21) | 1.62 (1.23‐2.12) | 21.1 |
| Lymphoma | 181 | 1.43 (1.13‐1.80) | 1.37 (1.07‐1.75) | 22.4 | 2.12 (1.68‐2.70) | 2.02 (1.57‐2.62) | 21.9 |
| CNS tumors | 245 | 1.74 (1.20‐1.80) | 1.13 (0.85‐1.49) | 22.8 | 1.71 (1.40‐2.08) | 1.48 (1.15‐1.91) | 22.4 |
| Testicular cancer | 156 | 1.27 (1.05‐1.54) | 1.27 (1.04‐1.56) | 22.3 | |||
| Malignant melanoma | 73 | 1.14 (0.71‐1.83) | 1.20 (0.73‐1.95) | 24.2 | 0.63 (0.44‐0.90) | 0.65 (0.45‐0.95) | 23.1 |
| Bone/soft tissue tumors | 99 | 1.79 (1.36‐2.36) | 1.62 (1.18‐2.22) | 22.7 | 1.63 (1.20‐2.20) | 1.52 (1.08‐1.24) | 23.1 |
| Female genital tract tumors | 44 | 1.45 (0.99‐2.11) | 1.29 (0.84‐1.98) | 23.4 | |||
| Other | 168 | 1.36 (1.05‐1.75) | 1.24 (0.94‐1.65) | 23.5 | 1.28 (1.03‐1.60) | 1.28 (1.01‐1.63) | 22.6 |
| All cancer | 1100 | 1.38 (1.26‐1.51) | 1.27 (1.14‐1.41) | 22.7 | 1.45 (1.32‐1.60) | 1.36 (1.22‐1.52) | 22.4 |
| Age at cancer diagnosis, y | |||||||
| <15 | 310 | 1.16 (1.00‐1.36) | 0.98 (0.81‐1.18) | 22.8 | 1.23 (1.05‐1.45) | 1.09 (0.90‐1.32) | 22.1 |
| 15‐24 | 790 | 1.53 (1.36‐1.72) | 1.46 (1.29‐1.66) | 22.7 | 1.61 (1.43‐1.82) | 1.54 (1.35‐1.76) | 22.5 |
Abbreviations: CI, confidence interval; HR, hazard ratio; CNS, central nervous system; FA, financial assistance.
Cancer sites are based on International Classification of Diseases (7th edition) site codes and on Manual of Tumor Nomenclature and Coding and International Classification of Diseases for Oncology (2nd edition) morphology codes.
Those who were receiving disability pensions were included (adjusted for year of birth and parental education).
Those who were receiving disability pensions were excluded (adjusted for year of birth and parental education).
Relative Risks and 95% Confidence Intervals for Unemployment in Cancer Survivors, by Cancer Site and Age at Diagnosis, Compared With Cancer‐Free Individuals
| Men | Women | |||
|---|---|---|---|---|
| Cancer Site | No. Unemployed/Total No. (% Not Employed) | RR (95% CI) | No. Unemployed/Total No. (% Not Employed) | RR (95% CI) |
| Noncancer | 25,009/570,080 (4.4) | 1.00 (Ref) | 33,982/543,580 (6.3) | 1.00 (Ref) |
| Leukemia | 6/221 (2.7) | 0.63 (0.29‐1.39) | 17/204 (8.3) | 1.42 (0.90‐2.23) |
| Lymphoma | 17/334 (5.1) | 1.19 (0.76‐1.90) | 23/222 (10.4) | 1.72 (1.18‐2.51) |
| CNS tumors | 20/286 (7) | 1.60 (1.06‐2.44) | 36/281 (12.8) | 2.11 (1.56‐2.86) |
| Testicular cancer | 43/644 (6.7) | 1.59 (1.19‐2.12) | ||
| Malignant melanoma | 5/106 (4.7) | 1.19 (0.50‐2.80) | 13/303 (4.3) | 0.75 (0.44‐1.27) |
| Bone/soft tissue tumors | 12/152 (7.9) | 1.84 (1.07‐3.16) | 10/122 (8.2) | 1.33 (0.73‐2.41) |
| Female genital tract tumors | 12/130 (9.2) | 1.49 (0.87‐2.53) | ||
| Other | 18/270 (6.7) | 1.64 (1.05‐2.55) | 23/356 (6.5) | 0.97 (0.64‐1.49) |
| All cancers | 121/2013 (6) | 1.42 (1.20‐1.69) | 134/1618 (8.3) | 1.36 (1.16‐1.61) |
| Age at cancer diagnosis, y | ||||
| <15 | 40/621 (6.4) | 1.38 (1.12‐1.71) | 47/517 (9.1) | 1.53 (1.16‐2.01) |
| 15‐24 | 81/1392 (5.8) | 1.51 (1.12‐2.04) | 87/1101 (7.9) | 1.30 (1.06‐1.59) |
Abbreviations: CI, confidence interval; CNS, central nervous system; Ref, reference category; RR, relative risk.
Cancer sites are based on International Classification of Diseases (7th edition) site codes and on Manual of Tumor Nomenclature and Coding and International Classification of Diseases for Oncology (2nd edition) morphology codes.
Those who were receiving disability pensions were excluded (adjusted for year of birth and parental education).
Work‐Related Income in Cancer Survivors, by Cancer Site and Age at Diagnosis, Compared With Cancer‐Free Individuals
| RR (95% CI) | |||||
|---|---|---|---|---|---|
| Variable | No. of Individuals | Median Income, NOK |
| Low Income | High Income |
| Men | |||||
| Noncancer | 543,788 | 379,794 | Ref | 1.00 (Ref) | 1.00 (Ref) |
| All cancer | 1884 | 366,369 | .07 | 1.06 (0.98‐1.16) | 0.92 (0.84‐1.01) |
| Cancer site | |||||
| Leukemia | 215 | 350,265 | .72 | 1.11 (0.86‐1.43) | 0.83 (0.62‐1.12) |
| Lymphoma | 317 | 368,100 | .34 | 1.08 (0.88‐1.34) | 1.00 (0.80‐1.25) |
| CNS tumors | 263 | 326,066 | .01 | 1.33 (1.09‐1.63) | 0.71 (0.53‐0.96) |
| Testicular cancer | 598 | 378,767 | .92 | 0.92 (0.77‐1.09) | 0.95 (0.80‐1.12) |
| Malignant melanoma | 99 | 397,139 | .38 | 0.83 (0.53‐1.30) | 1.08 (0.75‐1.56) |
| Bone/soft tissue tumors | 140 | 372,795 | .40 | 1.18 (0.88‐1.59) | 0.94 (0.67‐1.32) |
| Other | 252 | 362,391 | .35 | 1.07 (0.84‐1.36) | 1.02 (0.80‐1.31) |
| Age at cancer diagnosis. y | |||||
| <15 | 580 | 339,523 | < .01 | 1.19 (1.03‐1.38) | 0.85 (0.71‐1.02) |
| 15‐24 | 1304 | 378,934 | .64 | 1.01 (0.90‐1.13) | 0.95 (0.85‐1.06) |
| Women | |||||
| Noncancer | 508,288 | 272,077 | Ref | 1.00 (Ref) | 1.00 (Ref) |
| All cancer | 1479 | 259,088 | .28 | 1.20 (1.09‐1.31) | 0.94 (0.85‐1.05) |
| Cancer site | |||||
| Leukemia | 186 | 242,797 | .96 | 1.07 (0.81‐1.41) | 0.75 (0.53‐1‐05) |
| Lymphoma | 197 | 249,060 | .47 | 1.38 (1.10‐1.74) | 0.74 (0.53‐1,03) |
| CNS tumors | 244 | 222,414 | .03 | 1.38 (1.12‐1.69) | 0.81 (0.61‐1.08) |
| Malignant melanoma | 290 | 300,786 | .03 | 0.93 (0.73‐1.19) | 1.34 (1.12‐1.61) |
| Bone/soft tissue tumors | 112 | 261,811 | .90 | 1.35 (0.99‐1.83) | 0.85 (0.56‐1.28) |
| Female genital tract tumors | 118 | 276,719 | .86 | 1.27 (0.94‐1.73) | 0.95 (0.66‐1.39) |
| Other | 332 | 254,212 | .05 | 1.18 (0.96‐1.45) | 0.95 (0.75‐1.20) |
| Age at cancer diagnosis, y | |||||
| <15 | 469 | 243,655 | .17 | 1.18 (1.00‐1.39) | 0.76 (0.62‐0.94) |
| 15‐24 | 1010 | 268,911 | .80 | 1.21 (1.08‐1.35) | 1.03 (0.91‐1.16) |
Abbreviations: CI, confidence interval; CNS, central nervous system; NOK = Norwegian kroner; Ref, reference category; RR, relative risk.
Those who were receiving disability pensions were excluded.
The conversion rate in 2007 was 1 NOK = $0.17 US dollar.
P values are for differences in median income with cancer‐free individuals as the reference group (adjusted for year of birth and parental education).
Low income was defined as less than the 20th percentile of work‐related income in 2007 by year of birth and sex (adjusted for parental education).
High income was defined as greater than the 80th percentile of work‐related income in 2007 by year of birth and sex (adjusted for parental education).
Cancer sites are based on International Classification of Diseases (7th edition) site codes and on Manual of Tumor Nomenclature and Coding and International Classification of Diseases for Oncology (2nd edition) morphology codes.
Figure 1The median annual work‐related income in 2007 (in Norwegian kroner [NOK]; conversion rate, 1 NOK = $0.17 US dollars), with 95% confidence intervals, is illustrated according to birth year stratified by sex and cancer.
Relative Risk Ratios for Occupational Category and Income Differences in Cancer Survivors Compared With Cancer‐Free Individuals
| No. (% Employed in Occupational Category) | RRR for Occupational Category (95% CI) |
| ||||
|---|---|---|---|---|---|---|
| Employment Category/ISCO Group | Noncancer Controls | Cancer Survivors | Men | Women | Men | Women |
| Unskilled/ISCO 9 | 35,508 (3.9) | 109 (3.7) | 0.73 (0.54‐0.97) | 0.84 (0.60‐1.18) | .68 | .92 |
| Semiskilled blue collar/ISCO 6‐8 | 167,814 (18.3) | 531 (18) | 0.88 (0.78‐0.99) | 0.59 (0.40‐0.87) | .65 | .25 |
| Semiskilled white collar/ISCO 4 and 5 | 276,584 (30.2) | 879 (29.7) | 0.94 (0.82‐1.08) | 0.95 (0.84‐1.08) | .86 | .50 |
| Skilled/ISCO 1‐3 | 437,331 (47.7) | 1438 (49) | 1.00 (Ref) | 1.00 (Ref) | .02 | .08 |
Abbreviations: CI, confidence interval; ISCO, International Standard Classification of Occupation; Ref, reference category; RRR, relative risk ratio.
Analyses were adjusted for year of birth and parental education.
P values are for income differences within occupational categories for cancer survivors compared with noncancer controls (adjusted for year of birth and parental education).